Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
3 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Erythroid/megakaryocytic differentiation confers BCL-XL dependency and venetoclax resistance in acute myeloid leukemia.
Blood. 2023 Mar 30;141(13):1610-1625. doi: 10.1182/blood.2021011094.
Blood. 2023.
PMID: 36508699
Free PMC article.
Ex vivo venetoclax sensitivity testing predicts treatment response in acute myeloid leukemia.
Kuusanmäki H, Kytölä S, Vänttinen I, Ruokoranta T, Ranta A, Huuhtanen J, Suvela M, Parsons A, Holopainen A, Partanen A, Kuusisto MEL, Koskela S, Räty R, Itälä-Remes M, Västrik I, Dufva O, Siitonen S, Porkka K, Wennerberg K, Heckman CA, Ettala P, Pyörälä M, Rimpiläinen J, Siitonen T, Kontro M.
Kuusanmäki H, et al. Among authors: vanttinen i.
Haematologica. 2023 Jul 1;108(7):1768-1781. doi: 10.3324/haematol.2022.281692.
Haematologica. 2023.
PMID: 36519325
Free PMC article.
Item in Clipboard
Targeting CD33+ acute myeloid leukemia with GLK-33, a lintuzumab-auristatin conjugate with a wide therapeutic window.
Satomaa T, Pynnönen H, Aitio O, Hiltunen JO, Pitkänen V, Lähteenmäki T, Kotiranta T, Heiskanen A, Hänninen AL, Niemelä R, Helin J, Kuusanmaki H, Vänttinen I, Rathod R, Nieminen AI, Yatkin E, Heckman CA, Kontro M, Saarinen J.
Satomaa T, et al. Among authors: vanttinen i.
Mol Cancer Ther. 2024 Apr 2. doi: 10.1158/1535-7163.MCT-23-0720. Online ahead of print.
Mol Cancer Ther. 2024.
PMID: 38561023
Item in Clipboard
Cite
Cite